209 related articles for article (PubMed ID: 35959961)
1. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
Zhao Y; Zhou K; Xia X; Guo Y; Tao L
Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
3. Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1.
Tao L; Xia X; Kong S; Wang T; Fan F; Wang W
Pharmacol Res; 2024 Mar; 201():107091. PubMed ID: 38316371
[TBL] [Abstract][Full Text] [Related]
4. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
5. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
6. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
7. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
10. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
11. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
[TBL] [Abstract][Full Text] [Related]
12. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
[TBL] [Abstract][Full Text] [Related]
13. Metallointercalator [Ru(dppz)
Yusoh NA; Leong SW; Chia SL; Harun SN; Rahman MBA; Vallis KA; Gill MR; Ahmad H
ACS Chem Biol; 2020 Feb; 15(2):378-387. PubMed ID: 31898884
[TBL] [Abstract][Full Text] [Related]
14. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
18. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]